RxDoctor Payments Data

Jennifer Scott

Primary Care · Shawnee, KSNPI 1841284239

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $804 of the $904 with a category attached, or 88.9%. It is spread thinly across 15 manufacturers, the largest accounting for just 18.5% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2024 at $313 and has fallen 55.2% since, to $140 in 2025.

$904in general payments, 2019–2025

Across 51 payments — averaging $17.72 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$167
  • Novo Nordisk$103
  • Pfizer$102
  • Seagen Inc.$100
  • Lilly USA, LLC$98
  • Amgen$72
  • plus $261 from 9 others

What the payments were for

  • Food & beverage$80489%
  • Education$10011%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$904 in reported general payments places this provider in the 75th percentile of 56 primary care providers in Kansas.

See all primary care providers in Kansas

Medicare billing

Part B allowed, 2024
$29,207
Medicare patients
160
Services billed
529

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide40$55,851
OzempicSemaglutide29$33,790
EliquisApixaban23$33,347
TrulicityDulaglutide36$32,894
FarxigaDapagliflozin Propanediol17$20,581
XareltoRivaroxaban24$20,407
MyrbetriqMirabegron12$5,968
Fluticasone Propionate HfaFluticasone Propionate13$2,693
Atorvastatin Calcium346$2,544
Divalproex Sodium22$2,370
Rosuvastatin Calcium220$2,280
Omeprazole161$2,201
Levothyroxine Sodium188$1,498
Amlodipine Besylate232$1,035
Duloxetine Hcl36$964

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$98$88,74576 claims
Novo NordiskOzempic$103$33,79029 claims
PfizerEliquis$102$33,34723 claims
Johnson & JohnsonXarelto$25$20,40724 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 56 primary care providers in Kansas.

Other primary care in Shawnee

See the full list for Kansas

Where these figures come from

Is this you, or does something look wrong? →